What is Hangzhou Tigermed Consulting Co OCF Margin %?
Hangzhou Tigermed Consulting CoFRA:5HZ1 +5.41%86 OCF Margin % is 17.64% as of Mar. 2026, which is 6% below its 10-year median of 18.75. GuruFocus rates FRA:5HZ1 with a GF Score™ of 86/100 and a GF Value™ of €5.04 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Hangzhou Tigermed Consulting Co ranks better than 72.41% on this metric.
The historical rank and industry rank for Hangzhou Tigermed Consulting Co's OCF Margin % or its related term are showing as below:
FRA:5HZ1'
s OCF Margin % Range Over the Past 10 Years
Min: 15.58 Med: 18.75 Max: 31.28
Current: 17.51
During the past 13 years, the highest OCF Margin % of Hangzhou Tigermed Consulting Co was 31.28%. The lowest was 15.58%. And the median was 18.75%.
FRA:5HZ1's OCF Margin % is ranked better than 72.41% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.67
vs FRA:5HZ1: 17.51
Hangzhou Tigermed Consulting Co OCF Margin % Related Terms
Hangzhou Tigermed Consulting Co OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Tigermed Consulting Co OCF Margin % Chart
FRA:5HZ1 vs TMO, DHR, IDXX: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Tigermed Consulting Co OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Hangzhou Tigermed Consulting Co's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Tigermed Consulting Co (FRA:5HZ1) has a OCF Margin % of 17.64% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Hangzhou Tigermed Consulting Co and its competitors. This is near median its historical median of 18.75. Over the past decade, Hangzhou Tigermed Consulting Co's OCF Margin % has ranged from 15.58 to 31.28. According to the industry distribution chart, Hangzhou Tigermed Consulting Co ranks #56 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 27.6%.
Is Hangzhou Tigermed Consulting Co's OCF Margin % too high?
Hangzhou Tigermed Consulting Co's current OCF Margin % of 17.64% is near median its 10-year median of 18.75. Over the past 10 years, this metric has ranged from a low of 15.58 to a high of 31.28. The Medical Diagnostics & Research industry median OCF Margin % is 4.67. Hangzhou Tigermed Consulting Co's value of 17.64% is 277.7% above this industry median. Based on the distribution chart, Hangzhou Tigermed Consulting Co ranks #56 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Hangzhou Tigermed Consulting Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Tigermed Consulting Co's OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Hangzhou Tigermed Consulting Co ranks #56 out of 203 companies for OCF Margin %. This puts Hangzhou Tigermed Consulting Co in the upper half of its industry. The industry median OCF Margin % is 4.67. Hangzhou Tigermed Consulting Co's value of 17.64% is 277.7% above this benchmark. Historically, Hangzhou Tigermed Consulting Co's own OCF Margin % has ranged from 15.58 to 31.28 over the past decade. While the company's 10-year median is 18.75 vs. the industry median of 4.67, Hangzhou Tigermed Consulting Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.67, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Tigermed Consulting Co's current OCF Margin % of 17.64% is 277.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Hangzhou Tigermed Consulting Co and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Tigermed Consulting Co's current OCF Margin % is 17.64%, which is near median its own 10-year median of 18.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Tigermed Consulting Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co (FRA:5HZ1) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.04, compared to a current price of €3.90 — trading 22.6% below its estimated fair value. The current OCF Margin % is 17.64%, which is near median its 10-year median of 18.75 and 277.7% above the Medical Diagnostics & Research industry median of 4.67. Hangzhou Tigermed Consulting Co's overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Hangzhou Tigermed Consulting Co (FRA:5HZ1), the current OCF Margin % is 17.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Tigermed Consulting Co (FRA:5HZ1) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co stock appears to be undervalued.
The current stock price of €3.90 is trading 22.6% below its estimated GF Value™ of €5.04.
GuruFocus considers Hangzhou Tigermed Consulting Co to be Modestly Undervalued.
Key valuation signals for FRA:5HZ1:
OCF Margin %: 17.64% (near median its 10-year median of 18.75)
GF Value™: €5.04 vs. price of €3.90 (22.6% below fair value)
Industry Position: 277.7% above the Medical Diagnostics & Research median (#56 of 203)
No single metric tells the full story. See the FRA:5HZ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou Tigermed Consulting Co Business Description
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
86GF Score
Get the complete analysis for FRA:5HZ1
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HZ1 has been successfully added to your 
